8-K: Poseida Therapeutics Highlights Cell Therapy Advancements at R&D Day

Poseida Therapeutics shared updates on its allogeneic CAR-T therapy pipeline, including clinical and preclinical data across hematologic malignancies, autoimmune diseases, and solid tumors, during a virtual R&D Day.

Summary

• Poseida Therapeutics hosted a virtual R&D Day to present updates on its cell therapy research and development programs.
• The company is focused on developing allogeneic CAR-T therapies using its proprietary non-viral technology platform.
• Poseida's pipeline is organized around three pillars: hematologic malignancies, solid tumors, and autoimmune diseases.
• The company highlighted recent Phase 1 results for P-BCMA-ALLO1, its lead CAR-T program for multiple myeloma, showing a 91% overall response rate in BCMA-naive patients and 86% in BCMA-experienced patients.
• Preclinical data for P-CD19CD20-ALLO1, a dual CAR-T program, demonstrated high in vitro potency and strong in vivo antitumor activity.
• Poseida is also advancing P-BCMACD19-ALLO1 for autoimmune diseases, with preclinical data showing robust killing of patient-derived B cells.
• The company is developing innovative strategies to overcome challenges in applying CAR-T to solid tumors, including P-MUC1C-ALLO1 and P-PSMA-ALLO1.
• Poseida's in-house GMP manufacturing facility supports its broad cell therapy pipeline, with the capacity to produce over 100 doses per batch.
• The company has strategic collaborations with Roche and Astellas to further develop its cell therapy programs.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook on Poseida's technology and pipeline, with strong clinical and preclinical data, strategic partnerships, and a focus on addressing unmet medical needs. The company's innovative approaches and manufacturing capabilities are also highlighted, contributing to a strong positive sentiment.

Positives

• Poseida's non-viral technology platform allows for multi-gene insertion, enhancing functionality and safety features.
• The Cas-CLOVER gene editing system offers approximately 25-times greater fidelity than CRISPR-Cas9, improving safety and quality.
• Poseida's in-house GMP manufacturing facility enables scalable and lower-cost manufacturing.
• The company's Booster Molecule has enabled a scalable, lower cost manufacturing approach with the proven ability to generate cell yield up to over 100 doses per batch.
• Poseida's allogeneic approach simplifies patient access to CAR-T therapy compared to autologous methods.
• P-BCMA-ALLO1 showed a manageable safety profile with low incidence of severe CRS and ICANS.
• P-BCMACD19-ALLO1 has the potential to address both autoimmune diseases and oncology.
• Poseida's convertibleCAR technology, developed with Astellas, aims to improve CAR-T potency and persistence in solid tumors.
• The company's CAR-TCR technology addresses antigen heterogeneity in solid tumors.
• Poseida's manufacturing platform delivers T stem cell memory-rich products with high purity.

Negatives

• There are currently no CAR-T therapies approved for solid tumors, highlighting the challenges in this area.
• Antigen heterogeneity, differing lymphodepletion needs, on-target off-tumor toxicity, and a hostile tumor microenvironment are significant roadblocks for CAR-T in solid tumors.
• The company relies on third parties for various aspects of its business.
• There are risks and uncertainties associated with the development and regulatory approval of novel product candidates.
• The company has limited control over the efforts and resources that its collaborators devote to advancing development programs.
• The company may not receive the potential fees, reimbursements, and payments under the collaboration agreements.
• The company's collaborators may early terminate the collaboration, such that the company may not fully realize the benefits of the collaborations.
• There is significant donor variability in fold expansion during CAR-T cell manufacturing.
• Gene editing efficiency is donor-dependent.
• Final product phenotype and potency are donor-dependent.

Risks

• Interim data from clinical trials may change as more patient data becomes available and remain subject to audit and verification procedures.
• The company faces competition in its target markets.
• There is no guarantee that any of the company's product candidates will be shown to be effective or safe.
• The company's ability to finance continued operations is a risk.
• The company's reliance on third parties for various aspects of its business poses a risk.
• The company's ability to retain key scientific or management personnel is a risk.
• The company's ongoing and planned clinical trials are subject to risks and uncertainties.
• The company may not be able to protect its intellectual property.
• The company's manufacturing processes are subject to variability and may impact product quality and consistency.
• The company's collaborations may not be successful or may be terminated early.

Future Outlook

Poseida plans to continue advancing its clinical and preclinical programs, including dose expansion studies for P-BCMA-ALLO1 and IND-enabling studies for P-BCMACD19-ALLO1. The company also aims to further develop its manufacturing platform and explore new technologies for solid tumor therapies. They are also looking to expand partnerships.

Management Comments

• Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida Therapeutics, stated, 'We believe Poseida is well positioned to be a cell therapy leader based on the unique capabilities of our proprietary non-viral technology platform and our allogeneic TSCM-rich CAR-T approach.'
• Devon J. Shedlock, Ph.D., Chief Scientific Officer, Cell Therapy at Poseida Therapeutics, said, 'Building on the advantages of our non-viral allogeneic TSCM-rich approach, we are implementing several advanced technologies aimed at bringing the benefits of CAR-T therapy to patients with solid tumors.'
• Syed Rizvi, MD, Chief Medical Officer, noted the rapid responses seen in initial patients treated with P-BCMA-ALLO1 and the manageable safety profile compared to other CAR-T therapies.
• Thomas G. Martin, M.D., Clinical Professor of Medicine at UCSF, highlighted the potential of T stem cell memory-based therapies, such as P-BCMA-101, for long-term remissions and the reactivation of CAR-T cells by T cell engagers.

Industry Context

This announcement highlights Poseida's efforts to compete in the rapidly evolving cell therapy market, particularly in allogeneic CAR-T development. The company's focus on addressing challenges in solid tumors and autoimmune diseases positions it to potentially disrupt these areas. The collaborations with Roche and Astellas are significant, indicating industry validation of Poseida's technology and approach.

Comparison to Industry Standards

• P-BCMA-ALLO1's 91% ORR in BCMA-naive patients compares favorably to autologous CAR-T therapies like Abecma (53% ORR) and Carvykti (84% ORR), though cross-trial comparisons should be made with caution due to differences in study populations.
• P-BCMA-ALLO1's safety profile, with no grade 3 CRS or ICANS, appears better than autologous CAR-T therapies, which have higher rates of these toxicities.
• The median time to response of 16 days for P-BCMA-ALLO1 is faster than the median time to first response of 1 month for Carvykti.
• Poseida's allogeneic approach aims to address the limitations of autologous CAR-T, such as the time required for manufacturing and the limited patient reach.
• The company's focus on dual CAR-T and CAR-TCR technologies aligns with industry trends to overcome antigen escape and improve efficacy in solid tumors.
• Poseida's in-house GMP manufacturing facility and Booster Molecule technology aim to address the high cost and scalability challenges of cell therapy manufacturing, which are common issues in the industry.
• The collaboration with Astellas to develop convertibleCARs for solid tumors is a novel approach that could differentiate Poseida from competitors.
• The company's work in autoimmune diseases is part of a growing trend in the cell therapy field to expand beyond oncology.

Stakeholder Impact

• Shareholders: The positive clinical and preclinical data, along with strategic partnerships, are likely to be viewed favorably by investors.
• Patients: The development of new cell therapies offers hope for improved treatment options for cancer and autoimmune diseases.
• Employees: The company's progress and partnerships may boost employee morale and job security.
• Partners: The collaborations with Roche and Astellas are expected to strengthen these relationships and lead to further development opportunities.
• Suppliers: The company's manufacturing activities may lead to increased demand for raw materials and services.

Next Steps

• Continue enrolling patients in the Phase 1b dose expansion study for P-BCMA-ALLO1.
• Advance IND-enabling studies for P-BCMACD19-ALLO1 for autoimmune disease indications.
• File one or more INDs for an autoimmune disease indication with the U.S. Food and Drug Administration.
• Continue exploring dosing and lymphodepletion regimens for P-MUC1C-ALLO1.
• Provide a clinical data update for P-MUC1C-ALLO1 at the ESMO-IO Congress in December 2024.
• Advance preclinical development of P-PSMA-ALLO1 for prostate cancer.
• Optimize the convertibleCAR and MicAbody pairing with Xyphos.
• Continue to enhance the manufacturing platform, including AI-assisted donor screening and dynamic bioreactor environments.
• Advance the P-CD70-ALLO1 program towards clinical trials.

Key Dates

Keywords

allogeneic CAR-T, cell therapy, hematologic malignancies, autoimmune diseases, solid tumors, P-BCMA-ALLO1, P-CD19CD20-ALLO1, P-BCMACD19-ALLO1, P-MUC1C-ALLO1, P-PSMA-ALLO1, GMP manufacturing, non-viral gene editing, Cas-CLOVER, Astellas, Roche